{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:52:18Z","timestamp":1776048738505,"version":"3.50.1"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1750","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Ziftomenib (Komzifti \u2013 Kura), an oral menin inhibitor, has been approved by the FDA for treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. It is the second oral menin inhibitor to be approved in the US for this indication; revumenib (Revuforj) was approved in October 2025 for use in patients \u22651 year old.<\/jats:p>","DOI":"10.58347\/tml.2026.1750e","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:34:48Z","timestamp":1776047688000},"page":"e48-e49","source":"Crossref","is-referenced-by-count":0,"title":["Ziftomenib (Komzifti) for Acute Myeloid Leukemia"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,3,16]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:34:48Z","timestamp":1776047688000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1750e"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":0,"journal-issue":{"issue":"1750","published-online":{"date-parts":[[2026,3,16]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1750e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}